Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients... Show more
agilon health, inc. (NYSE: AGL) is a healthcare services company that partners with primary care physicians (PCPs) to deliver a total care payment model for senior patients. The company's platform enables PCPs to manage the total cost of care through value-based arrangements with payors, focusing on Medicare Advantage plans. agilon provides technology, data analytics, and operational support to facilitate risk-bearing contracts, where physicians share in savings from efficient care delivery.
In the competitive healthcare industry, agilon differentiates through its physician-centric approach in the growing value-based care segment. With exposure to senior demographics and Medicare trends, its business model benefits from rising demand for cost-effective care amid aging populations. Recent stock behavior aligns with improving operational metrics and sector tailwinds, despite past challenges like membership declines.
Over the last 30 days, AGL stock rose +118%, from a close of $11.00 on March 23 to $24.01 on April 21. The movement was highly volatile and trend-driven upward, with a sharp post-split rally peaking at $30.94 on April 16 before a pullback. Trading volume spiked during the advance, reflecting heightened investor interest.
For the past quarter, the stock gained +1%, moving from $23.83 on January 21 to $24.01. Performance was range-bound with significant volatility, dipping to a low of $7.91 in late March before recovering. The quarter featured a steady recovery phase after earnings, punctuated by the reverse split impact.
The primary catalyst was agilon health's 1-for-25 reverse stock split, effective March 30, which adjusted shares to boost the per-share price and aid Nasdaq compliance. Post-split, the stock surged as investors reassessed its turnaround potential, fueled by Q4 2025 results showing revenue of $1.57 billion—beating estimates by 7.2%—despite an EPS miss.
Sector sentiment shifted positively, with AGL shares soaring alongside peers like Astrana Health and Evolent Health amid broader healthcare momentum. Analyst actions, including a "Buy" rating with a raised price target, added tailwinds. Improving vitals, such as guidance for near break-even EBITDA in 2026 versus prior-year losses, enhanced market confidence, driving the volatile uptrend in stock price analysis.
The quarter's modest +1% gain stemmed from sustained narratives around operational improvements and strategic moves. Q4 earnings in late February highlighted revenue growth but underscored losses, leading to an initial dip; however, forward guidance signaled progress toward profitability, supporting recovery.
The reverse stock split addressed listing risks, restoring investor appeal. Macro factors like Medicare Advantage enrollment trends and value-based care adoption provided a favorable backdrop. Institutional interest grew as peers advanced, with AGL benefiting from comparative strength in outpatient and specialty care benchmarking. Cumulative impact from these elements offset volatility, stabilizing price movement.
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from a library of hundreds scanning thousands of tickers. These curated bots employ diverse strategies, including trend-following, mean reversion, and momentum plays, across various timeframes from intraday to long-term. Performance metrics such as win rate, average return, and Sharpe ratio highlight their edge, with only the most relevant and high-achieving models featured based on recent market conditions. Traders can explore, backtest, and deploy these bots to enhance their stock analysis and automate trades. Visit the page to discover bots tailored to current market trends.
Investors should monitor Q1 2026 earnings on May 6 for updates on revenue, membership, and EBITDA progress toward 2026 guidance. Industry trends in value-based care and Medicare policy changes could impact risk-bearing contracts. Macroeconomic factors like healthcare spending and inflation in medical costs remain key. Strategic developments, including partnerships or platform expansions, may signal growth. Risks include execution on cost controls and competition, while catalysts like analyst revisions or peer earnings could sway sentiment in market trends.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
AGL saw its Momentum Indicator move above the 0 level on June 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 74 similar instances where the indicator turned positive. In of the 74 cases, the stock moved higher in the following days. The odds of a move higher are at .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AGL advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 153 cases where AGL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for AGL moved out of overbought territory on June 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 53 cases where AGL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AGL turned negative on June 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AGL broke above its upper Bollinger Band on June 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.406) is normal, around the industry mean (224.384). P/E Ratio (0.000) is within average values for comparable stocks, (120.761). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.438). AGL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (0.323) is also within normal values, averaging (2.531).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HospitalNursingManagement